NASDAQ · RVPH
Healthcare · Biotechnology
$0.35
Down-$0.01 (-1.43%)
Updated Aug 23, 2026, 12:34 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RVPH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning RVPH.
RVPH research
Company profile and research snapshot.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 8, 2026 | Maxim Group | Hold | — |
| Mar 5, 2026 | D. Boral Capital | Hold | — |
| Jan 5, 2026 | Chardan Capital | Buy | — |
| Dec 23, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 23, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.39) by 50 percent. This is a 92.08 percent increase over losses of $(2.40) per share
Yahoo · Jun 26, 2026
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and ana
Benzinga · Mar 9, 2026
Benzinga · Mar 5, 2026
D. Boral Capital analyst Jason Kolbert downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RVPH.
